Firefly Neuroscience Revenue Soars, But Losses Deepen Amid Evoke Acquisition

Ticker: AIFF · Form: 10-Q · Filed: Nov 12, 2025 · CIK: 803578

Sentiment: bearish

Topics: Biotechnology, Medical Devices, Going Concern, Acquisition, Net Loss, Revenue Growth, Cash Burn

Related Tickers: AIFF

TL;DR

**AIFF's revenue jumped, but their massive losses and 'going concern' warning mean this stock is a high-risk gamble on future capital raises and successful integration of Evoke.**

AI Summary

FIREFLY NEUROSCIENCE, INC. (AIFF) reported a significant increase in revenue for the nine months ended September 30, 2025, reaching $730 thousand, up from $55 thousand in the same period of 2024. Despite this revenue growth, the company experienced a substantial net loss of $17.402 million for the nine months ended September 30, 2025, compared to a net loss of $6.675 million in 2024. This increased loss was primarily driven by a $9.369 million change in derivative fair value and a $1.353 million loss on settlement. The company's cash position improved significantly, with cash increasing to $4.325 million as of September 30, 2025, from $1.810 million at December 31, 2024, largely due to $11.369 million in financing activities, including $8.838 million from warrant exercises. A key business change was the acquisition of Evoke Neuroscience, Inc. on April 30, 2025, for $3.000 million in cash, contributing to a $2.360 million net cash outflow for acquisitions. The company continues to face substantial doubt about its ability to continue as a going concern due to recurring losses and negative operating cash flow of $6.389 million for the nine months ended September 30, 2025, and relies on raising additional capital.

Why It Matters

For investors, AIFF's substantial revenue growth to $730 thousand is a positive signal, but the escalating net loss of $17.402 million and the 'going concern' warning are critical red flags, indicating significant operational challenges and reliance on external funding. The acquisition of Evoke Neuroscience for $3.000 million suggests a strategic move to expand its product offerings, potentially increasing its competitive footprint in the neuro-technology market against rivals. However, the company's ability to integrate Evoke and achieve profitability remains a major concern, impacting future stock performance and employee stability. Customers might benefit from an expanded product portfolio, but the company's financial instability could pose long-term risks to product support and innovation.

Risk Assessment

Risk Level: high — The company explicitly states it has an accumulated deficit of $108.896 million and negative cash flow from operating activities of $6.389 million for the nine months ended September 30, 2025, which "raise substantial doubt about the Company's ability to continue as a going concern." This, coupled with recurring losses and minimal revenue, indicates a precarious financial position.

Analyst Insight

Investors should exercise extreme caution and consider AIFF a highly speculative investment. Monitor future capital raises and the successful integration of Evoke Neuroscience closely, as the company's survival hinges on these factors. Avoid significant positions until there's clear evidence of sustained profitability and positive operating cash flow.

Financial Highlights

debt To Equity
0.28
revenue
$730K
operating Margin
-870.5%
total Assets
$12.407M
total Debt
$2.750M
net Income
-$17.402M
eps
-$0.20
gross Margin
63.4%
cash Position
$4.325M
revenue Growth
+1227.3%

Revenue Breakdown

SegmentRevenueGrowth
Total Revenue$730K+1227.3%

Key Numbers

Key Players & Entities

FAQ

What is Firefly Neuroscience's revenue for the nine months ended September 30, 2025?

Firefly Neuroscience, Inc. reported revenue of $730 thousand for the nine months ended September 30, 2025. This represents a significant increase from $55 thousand in the same period of 2024.

What was Firefly Neuroscience's net loss for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Firefly Neuroscience, Inc. reported a net loss of $17.402 million. This is a substantial increase from the $6.675 million net loss reported for the same period in 2024.

Did Firefly Neuroscience acquire any companies in 2025?

Yes, on April 30, 2025, Firefly Neuroscience, Inc. acquired all outstanding stock of Evoke Neuroscience, Inc., a privately held company. The company paid $3.000 million in cash for this acquisition.

What is the 'going concern' risk for Firefly Neuroscience?

Firefly Neuroscience, Inc. has an accumulated deficit of $108.896 million and negative cash flow from operating activities of $6.389 million for the nine months ended September 30, 2025. These conditions, along with recurring losses, raise substantial doubt about the company's ability to continue as a going concern.

How much cash did Firefly Neuroscience have as of September 30, 2025?

As of September 30, 2025, Firefly Neuroscience, Inc. had a cash balance of $4.325 million. This is an increase from $1.810 million at December 31, 2024.

What were the primary sources of cash for Firefly Neuroscience in the nine months ended September 30, 2025?

The primary sources of cash for Firefly Neuroscience, Inc. during the nine months ended September 30, 2025, came from financing activities, totaling $11.369 million. This included $2.531 million from the sale of shares and $8.838 million from the exercise of warrants.

What is the current number of outstanding common shares for AIFF?

As of November 6, 2025, there were a total of 13,482,511 shares of Firefly Neuroscience, Inc.'s common stock outstanding.

What is Firefly Neuroscience's business model?

Firefly Neuroscience, Inc. is engaged in the development, marketing, and distribution of medical devices and technology. Their focus is on high-resolution visualization and evaluation of the complex neuro-physiological interconnections of the human brain.

What was the impact of the change in derivative fair value on AIFF's financials?

The change in derivative fair value resulted in a loss of $9.369 million for Firefly Neuroscience, Inc. during the nine months ended September 30, 2025. This significant non-operating expense contributed substantially to the company's increased net loss.

How does Firefly Neuroscience plan to address its 'going concern' issues?

Management of Firefly Neuroscience, Inc. has a reasonable expectation that the company can continue raising additional capital to sustain operational existence for the foreseeable future. However, there is no assurance that additional funding will be obtained on satisfactory terms or at all.

Risk Factors

Industry Context

The neuroscience sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on external financing to fund innovation and clinical trials. The competitive landscape includes established pharmaceutical giants and numerous biotech startups, with success often hinging on breakthrough therapies and strategic partnerships.

Regulatory Implications

As a neuroscience company, Firefly is subject to stringent regulations from bodies like the FDA. Delays in clinical trials, failure to obtain regulatory approval, or post-market safety issues can have severe financial and operational consequences. Compliance with evolving data privacy and security regulations is also critical.

What Investors Should Do

  1. Monitor future financing rounds closely, as the company's going concern status is heavily dependent on raising capital.
  2. Analyze the integration progress and performance of Evoke Neuroscience to assess the strategic rationale and potential return on investment.
  3. Scrutinize the drivers of the increased net loss, particularly the impact of derivative fair value changes and settlement losses, in subsequent filings.
  4. Evaluate the company's ability to generate positive operating cash flow in the near future to alleviate going concern risks.

Key Dates

Glossary

Accumulated deficit
The total net losses of a company since its inception, minus any net profits. It represents a negative retained earnings balance. (Indicates the company's historical unprofitability, with a deficit of $108.896 million as of September 30, 2025.)
Change in derivative fair value
The unrealized gain or loss resulting from changes in the market value of financial instruments like options or warrants. (A significant factor contributing to the increased net loss, with a $9.369 million negative impact in the nine months ended September 30, 2025.)
Going concern
An assumption that a company will continue to operate for the foreseeable future, typically at least the next 12 months. (The company faces substantial doubt about its ability to continue as a going concern, necessitating disclosure and potential mitigation strategies.)
Warrant exercises
The process by which holders of warrants (options to buy stock at a specific price) convert them into actual shares of the company's stock. (Generated $8.838 million in cash for the company, contributing to the improved cash position.)
Net cash used in operating activities
The amount of cash a company has spent on its core business operations over a period, excluding investing and financing activities. (A negative $6.389 million for the nine months ended September 30, 2025, indicates the business is consuming cash to operate.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Firefly Neuroscience has demonstrated remarkable revenue growth, increasing from $55 thousand to $730 thousand. However, this top-line improvement has been overshadowed by a significant widening of the net loss, from $6.675 million to $17.402 million, largely due to non-operational factors like derivative fair value changes. While the cash position has improved substantially due to financing activities, the company continues to face substantial doubt regarding its ability to continue as a going concern, with operating cash burn remaining a key concern.

Filing Stats: 4,700 words · 19 min read · ~16 pages · Grade level 17.1 · Accepted 2025-11-12 06:06:43

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 1 Condensed Consolidated Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024 1 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 2 Condensed Consolidated Statements of Equity (Deficit) for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 3 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (Unaudited) 4 Notes to Condensed Consolidated Financial Statements (Unaudited) 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 27 Item 4.

Controls and Procedures

Controls and Procedures 27

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 28 Item 1A.

Risk Factors

Risk Factors 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28 Item 3. Defaults Upon Senior Securities 28 Item 4. Mine Safety Disclosures 28 Item 5. Other Information 28 Item 6. Exhibits 29

Signatures

Signatures 30 i Part I. Financial Information

Financial Statements

Item 1. Financial Statements. FIREFLY NEUROSCIENCE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2025 AND DECEMBER 31, 2024 (IN THOUSANDS, EXCEPT SHARE DATA) September 30, December 31, 2025 2024 (Unaudited) ASSETS Current assets Cash $ 4,325 $ 1,810 Other receivables 184 121 Prepaid expenses 841 697 Inventory 80 - Total current assets 5,430 2,628 Non current assets Prepaid expenses 669 1,657 Equipment, net 235 136 Intangible assets, net 898 180 Goodwill 5,175 - Total non current assets 6,977 1,973 TOTAL ASSETS $ 12,407 $ 4,601 LIABILITIES Current liabilities Trade payables $ 1,345 $ 1,816 Accrued liabilities 658 1,626 Deferred revenue 238 13 Convertible promissory note, net of unamortized discount - 694 Deemed dividend liability - - Contingent consideration payable 478 - Derivative liability - 827 Total current liabilities 2,719 4,976 Non current liabilities Deferred revenue 31 - TOTAL LIABILITIES $ 2,750 $ 4,976 COMMITMENTS AND CONTINGENCIES (Note 12) SHAREHOLDERS' EQUITY (DEFICIT) Preferred shares, $ 0.0001 par value: 1,000,000 shares authorized; nil issued and outstanding at September 30, 2025 and December 31, 2024 - - Common shares, $ 0.0001 par value: 100,000,000 shares authorized; 13,477,012 and 8,122,060 issued and outstanding at September 30, 2025 and December 31, 2024, respectively 1 1 Additional paid-in capital 118,552 86,708 Accumulated deficit ( 108,896 ) ( 87,084 ) TOTAL SHAREHOLDERS' EQUITY (DEFICIT) 9,657 ( 375 ) TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 12,407 $ 4,601 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 1 FIREFLY NEUROSCIENCE, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 (IN THOUSANDS, EXCEPT SHARE AND PER SHARE D

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing